Abstract: In an embodiment, a method for loading a powder substance (10) into recesses (200) provided at a stent (S) surface, the method comprises: applying compression (100) to the powder substance (10) to thereby form tablets insertable into said recesses (200), inserting the tablets into the recesses (200) of the stent (S).

Abstract: In an embodiment, a stent (S) implantable in a vessel of a patient, comprises recesses (200) loaded with an active principle with anti-inflammatory activity (10) and an active principle with anti-proliferative activity (20). The active principle with anti-inflammatory activity (10) and the active principle with anti-proliferative activity (20) have respective formulations, whereby the active principle with anti-inflammatory activity (10)and the active principle with anti-proliferative activity (20) have respective release kinetics as a function of said formulations, with the release of the active principle with anti-inflammatory activity (10) being faster than the release of the active principle with anti-proliferative activity (20).

Abstract: A stent for the controlled release of at least two active principles having anti-proliferative activity and anti-inflammatory activity, respectively, with different release kinetic profiles from each other.

Abstract: In an embodiment, a method for loading a powder substance (10) into recesses (200) provided at a stent (S) surface, the method comprises: applying compression (100) to the powder substance (10) to thereby form tablets insertable into said recesses (200), inserting the tablets into the recesses (200) of the stent (S).

Abstract: Composition for delivery of at least one active principle at the implantation site of an implant device, including: at least one active principle, and at least a first excipient combined with the at least one active principle, wherein the at least a first excipient is selected among fatty acids with a linear or branched, saturated chain, including a number of carbon atoms between 14 and 36.

Abstract: Composition for delivery of at least one active principle at the implantation site of an implant device, including: at least one active principle, and at least a first excipient combined with the at least one active principle, wherein the at least a first excipient is selected among fatty acids with a linear or branched, saturated chain, including a number of carbon atoms between 14 and 36.

Abstract: The present invention provides a stent for implantation at a site within a human or animal body comprising: an expandable body having an inner surface and an outer surface; and treatment agents applied to the outer surface of the expandable body, the treatment agents comprising a combination of Paclitaxel and FK506 or their derivatives or analogues.

Abstract: A process for depositing an active substance on selected regions of the surface of a stent, comprising: (i) providing the active substance in at least one form selected from the group consisting of a powder and a paste; and (ii) depositing the active substance on the selected regions of the surface of the stent. Preferably, the active substance comprises or consists essentially of FK506, such as FK506 in the form of a powder with a grain size smaller than 15 micron or a paste with a base of FK506 with a viscosity not lower than 100,000 to 120,000 cps.

Abstract: A carrier for delivering at least one active principle at an intraluminal site. The carrier includes a carrier body, such as a stent. The carrier body is provided with one or more reservoirs. The reservoirs contain nanoparticles which convey at least one active principle. The nanoparticles also comprise a substance having characteristics of preferential affinity attraction to a desired region at the intraluminal site. The nanoparticles can migrate toward the preferred region.

Abstract: A process for depositing an active substance on selected regions of the surface of a stent, comprising: (i) providing the active substance in at least one form selected from the group consisting of a powder and a paste; and (ii) depositing the active substance on the selected regions of the surface of the stent. Preferably, the active substance comprises or consists essentially of FK506, such as FK506 in the form of a powder with a grain size smaller than 15 micron or a paste with a base of FK506 with a viscosity not lower than 100,000 to 120,000 cps.

Abstract: A stent comprising a plurality of annular elements aligned in the longitudinal direction of extension of the stent and selectively expandable between a radially-contracted condition and a radially-expanded condition as well as a series of connecting elements that extend in the longitudinal direction of extension of the stent to connect the annular elements. The annular elements and the connecting elements are made, respectively, of non-biodegradable material and of biodegradable material. The structure of the stent thus comprises a part of non-biodegradable material, destined to remain long-term at the site of implantation, and a part of biodegradable material, destined to disappear within a longer or shorter period after implantation.

Abstract: A device and method for performing a therapeutic treatment at a treatment site in a patient's vessel, the device configured to be introduced by means of a catheter, the device including an expandable portion capable of being expanded between a contracted position and a deployed position at the treatment site, such as to achieve an angioplasty treatment at the site, and a conveyor portion capable of receiving cells for cellular therapy and delivering the cells to the treatment site such that the angioplasty and cellular therapy procedures are performed substantially simultaneously.

Abstract: A carrier for delivering at least one active principle at an intraluminal site. The carrier includes a carrier body, such as a stent. The carrier body is provided with one or more reservoirs. The reservoirs contain nanoparticles which convey at least one active principle. The nanoparticles also comprise a substance having characteristics of preferential affinity attraction to a desired region at the intraluminal site. The nanoparticles can migrate toward the preferred region.

Abstract: The present invention provides a stent for implantation at a site within a human or animal body comprising: an expandable body having an inner surface and an outer surface; and treatment agents applied to the outer surface of the expandable body, the treatment agents comprising a combination of Paclitaxel and FK506 or their derivatives or analogues.

Abstract: A process for depositing an active substance on selected regions of the surface of a stent, comprising: (i) providing the active substance in at least one form selected from the group consisting of a powder and a paste; and (ii) depositing the active substance on the selected regions of the surface of the stent.

Abstract: A carrier for delivering at least one active principle at an intraluminal site. The carrier includes a carrier body, such as a stent. The carrier body is provided with one or more reservoirs. The reservoirs contain nanoparticles which convey at least one active principle. The nanoparticles also comprise a substance having characteristics of preferential affinity attraction to a desired region at the intraluminal site. The nanoparticles can migrate toward the preferred region.

Abstract: The present invention is directed to fluorescent dyes and its valence tautomers of the formula wherein Q represents a conjugated moiety that increases the fluorescent quantum yield of the compound; R.sub.1 is a functionalized group of the formula--(CH.sub.2).sub.j Y, wherein Y is selected from the group consisting of SO.sub.3 H, COOH, NH.sub.2, CHO, NCS, epoxy, phthalimido, and COOZ, wherein Z represents a leaving group; R.sub.2 is a functionalized group of the formula --(CH.sub.2).sub.k Y', wherein Y' is selected from the group consisting of SO.sub.3 H, COOH, NH.sub.2, CHO, NCS, epoxy, phthalimido, and COOZ, wherein Z represents a leaving group; M.sup.+ is a counterion selected from the group consisting of ammonium, alkali metal cations, and alkaline earth metal cations; n=1 to 4; m=1 to 4; j=2 to 10; and k=2 to 10.

Abstract: A method of preparing biological implantation material fixed by means of aldehydes, in which the excess aldehyde is bound by treatment with an aminocarboxylic acid and the acid is selected from compounds of the general formula: ##STR1## in which n is 1 or 2 and X is a sulpho- (--SO.sub.3 H) or phosphono- (--PO.sub.3 H) group, and mixtures of such compounds.